well-execut quarter multipl expand remain neutral valuat
share higher thursday trade session follow morn
earn releas revenu ep consensu manag rais ep
guidanc midpoint rais beat view conserv
given move part ge biopharma acquisit dental ipo given
commentari around turn well-execut controversi area china
industri increment confid abil deliv
beyond follow pend ge biopharma acquisit dental ipo
forward estim remain larg unchang view financ assumpt
conserv maintain premium peer median ep multipl
pt rise remain neutral valuat
result report organ revenu growth
consensu life scienc revenu grew organ
street diagnost also grew organ
consensu environment grew cc line
street dental revenu declin organ street
gross margin declin yoy oper margin declin yoy believ
due fx headwind stronger usd dental mix slightli off-set strong life
scienc oper margin yoy improv on-going ep
street estim
outlook manag maintain organ revenu growth assumpt
suggest could closer street
rais non-gaap ep guidanc midpoint rang move
street beat essenti guid cent
street penni street accordingli lower
earn estim maintain number view
conserv relat move part potenti ge biopharma acquisiton
dental spin-off addit maintain conserv financ assumpt
regard acqusit dental spin debt issuanc
interest though manag believ debt issu lower rate
use interest ge relat debt instead assumpt
would lead ep upsid
stock view well execut quarter view
manag commentari confid estim appear
conserv howev remain neutral valuat page two busi
ep
debt total capit
competit regul reimburs acquisit integr
conglomer focus healthcar environment product
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
china execut opinion head quarter main topic interest
small molecul biopharma china peer seen recent weak top
gener econom uncertainti saw growth china quarter reflect
manag describ rel broad strength life scienc diagnost beckman
coulter diagnost leica biosystem point particular weak small
molecul biopharma end market though note larg molecul biopharma larg biolog
focus stronger grower particular strength cell gene therapi
industri tough comp forward uncertainti industri end market hach face
difficult comp larg chines govern relat project experienc low
singl digit growth manag note see particularli neg trend
order book remain solid though commentari bullish across area
portfolio note industri end market lumpi larg municip project
revenu view industri end-market estim conserv reason
given manag reassur commentari overli concern end market
execut remain danah strength team gave view posit commentari
implement new busi point strength custom intimaci vs give
sale forc broader bag product particularli ahead larg potenti ge biopharma
acquisit given commentari compani track record success implement
well reason deal valuat continu believ attract
addit busi portfolio
page
million except share per share data
updat
net incom common
good sold
good sold
good sold
current disclosur inform compani locat
